Abstracts tagged "joint protection"

Abstract Number: 1106 • 2016 ACR/ARHP Annual Meeting
Test of the Spleen Tyrosine Kinase Inhibitor Fostamatinib in a Translational Joint Tissue Model Show Significant Effect on Bone, but Not on Synovial Tissue
Cecilie F. Kjelgaard-Petersen^1,2, Anne C. Bay-Jensen³, Thorbjørn G. Christiansen⁴, Morten Asser Karsdal³, Per Hägglund² and Christian S. Thudium¹, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁴Gentofte University Hospital, Orthopaedicsurgery unit, Gentofte, Denmark
Background/Purpose: The Spleen tyrosine kinase (Syk) inhibitor fostamatinib was not approved as treatment for rheumatoid arthritis (RA) due to insufficient effect on joint structure in…
Abstract Number: 1181 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naïve Patients with Early Active Rheumatoid Arthritis (Duration ≤2 Years): Results of an Exploratory Phase 2 MRI Study
Philip G. Conaghan¹, M. Østergaard², C. Wu³, D. van der Heijde⁴, F. Irazoque-Palazuelos⁵, P. Hrycaj⁶, Z. Xie⁷, R. Zhang⁷, B.T. Wyman⁷, J.D. Bradley⁷, K. Soma⁷ and B. Wilkinson⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom, ²Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³BioClinca Inc., Newark, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Servicio de Reumatología, Hospital Angeles Mocel, Mexico City, Mexico, ⁶Poznan University of Medical Sciences, Poznan, Poland, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Inflammation of the synovium and in particular the bone marrow, as assessed by magnetic resonance imaging (MRI), have been identified as prognostic indicators of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].